MoonLake Secures Funding
MoonLake Immunotherapeutics prices upsized $200 million public offering to fund R&D.
MoonLake Immunotherapeutics priced an upsized public offering at $20.00 per share on June 23, 2026, raising approximately $200 million — up from an initial $150 million target announced just one day earlier. The Swiss clinical-stage biotech sold 9,000,000 Class A ordinary shares, plus pre-funded warrants for up to 1,000,000 additional shares, with the deal set to close around June 25, according to GlobeNewswire.
The rapid upsize signals strong institutional demand. It follows landmark one-year trial results for sonelokimab, MoonLake's lead drug for a painful inflammatory skin condition called Hidradenitis Suppurativa (HS). The company plans to use the proceeds to fund the drug's development and, if approved, its commercial launch, according to GlobeNewswire.
Strong Clinical Data Drove the $50 Million Upsize
Just two days before pricing, on June 21, MoonLake released Week 52 Phase 3 trial results for sonelokimab. The data showed a 67.2% response rate in adults using the HiSCR75 scale — a standard measure of HS improvement. That figure beat competing biologics by more than 10 percentage points at the one-year mark, according to ADVFN.
CEO Dr. Jorge Santos da Silva called the results confirmation that sonelokimab is a "best-in-disease therapy." The drug also achieved complete clearance in 33.1% of patients. Those numbers convinced institutions to pile in, pushing the offering from $150 million to $200 million within 24 hours. Leerink Partners, Guggenheim Securities, Cantor, and LifeSci Capital served as joint bookrunning managers, per GlobeNewswire.
What Sonelokimab Is — and Why It Matters
Sonelokimab is a Nanobody — a tiny antibody roughly one-tenth the size of traditional drugs like Humira. Its small size may let it penetrate deeper into tissue, which is key for HS. HS causes painful, recurring abscesses under the skin. About 2 million U.S. patients have been identified with the condition via real-world health data, according to Yahoo Finance.
The HS treatment market is forecast to reach $7.8 billion by 2034. MoonLake plans to file for FDA approval — called a Biologics License Application — by late September 2026. If that goes smoothly, a U.S. commercial launch could come in the second half of 2027. The FDA already granted the drug Fast Track status for another condition, Palmoplantar Pustulosis, in February 2026, according to GlobeNewswire.
A Comeback Story With Some Lingering Doubts
This raise is a rebound move. In September 2025, MoonLake's stock crashed more than 80% in a single day after one part of its Phase 3 trial — called VELA-2 — missed its statistical target. A high placebo response rate muddied the results. A securities fraud lawsuit followed in October 2025, alleging leadership overstated the drug's advantages, according to MarketScreener.
Not everyone is fully convinced the worst is over. CEO Santos da Silva sold 150,000 shares in April 2026, and insiders have collectively sold over $70 million in stock over the past three months. The company also burned through approximately $224 million in free cash flow over the past year. Before this offering, MoonLake held $357.9 million in cash as of March 31, 2026, according to Yahoo Finance.
What the $200 Million Buys the Company
The new capital extends MoonLake's runway well past 2027 — covering the critical transition from research to sales. The shelf registration that enabled this offering was filed with the SEC and became effective May 1, 2026. Underwriters also hold a 30-day option to buy an additional 1,500,000 shares, which could push total proceeds even higher, according to GlobeNewswire.
Analysts at Clear Street described sonelokimab as having "blockbuster potential," saying it could challenge UCB's Bimzelx as the top IL-17 inhibitor for HS. MoonLake's market cap stands at roughly $1.61 billion. With a BLA filing just months away and a commercialization clock now ticking, the $200 million raise is less about survival and more about scaling up, according to Yahoo Finance.
Sentiment
NeutralPublishers
5
Articles
5
Reach
5
